溃疡性结肠炎缓解评估:临床、内窥镜和组织学指标作为复发预测指标的关系。

IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY
Francisca Carvajal, Karin Herrera, Paulina Núñez, Lilian Flores, Andrea Córdova, Gonzalo Pizarro, Pamela San Martín, Luis Contreras, Rodrigo Quera
{"title":"溃疡性结肠炎缓解评估:临床、内窥镜和组织学指标作为复发预测指标的关系。","authors":"Francisca Carvajal, Karin Herrera, Paulina Núñez, Lilian Flores, Andrea Córdova, Gonzalo Pizarro, Pamela San Martín, Luis Contreras, Rodrigo Quera","doi":"10.1016/j.gastrohep.2025.502437","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In ulcerative colitis (UC), STRIDE-II consensus has established the long-term goal of achieving endoscopic remission (ER), which helps reduce inflammatory burden, prevent permanent intestinal damage, and improve patient´s quality of life. However, achieving histological remission (HR) is also associated with a lower risk of experiencing outbreaks of inflammatory activity, the need for corticosteroids, hospitalizations, and the development of colorectal cancer.</p><p><strong>Objective: </strong>Evaluate the role of ER and HR in the development of inflammatory activity flares in patients who have achieved these long-term goals and are being followed in the Inflammatory Bowel Disease (IBD) Program.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on patients with UC treated in the IBD Program at the Universidad de los Andes, between January 2021 and April 2023. Patients with ER (Mayo Endoscopic Index [MEI] 0) or endoscopic response (MEI 1), with at least one year of follow-up, were included. HR was defined using the Nancy (<2), Geboes (<2), and Robarts (<3) indices. Inflammatory activity was assessed by a Partial Mayo Index (PMI) ≥2 and fecal calprotectin >250 µg/g.</p><p><strong>Results: </strong>A total of 84 patients were included, 57.1% were women, with a median age of 37 years (IQR 31-45). During follow-up, 71 patients continued in the study, and 24 (31%) experienced inflammatory flares. In the MEI 0 group, the percentage of flares at 12 and 44 months was 15% and 53%, respectively, compared to 43% and 67% in the MEI 1 group (p = 0.0302). PMI and fecal calprotectin levels were significantly lower in MEI 0 than in MEI 1 (p < 0.001 and p < 0.05, respectively). Although the Nancy, Geboes, and Robarts indices showed significant differences between MEI 0 and MEI 1, none were associated with a lower risk of flares in the MEI 0 group. No cases of colorectal neoplasia or need for surgery were reported during follow-up.</p><p><strong>Conclusion: </strong>In this cohort, ER is a significant predictor of the development of inflammatory flares in patients with UC, while HR did not show a clear impact in this regard. Further studies are needed to clarify the role of HR as a therapeutic target in UC.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502437"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluación de la Remisión en Colitis Ulcerosa: Relación entre Marcadores Clínicos, Endoscópicos e Histológicos como Predictores de Recaída.\",\"authors\":\"Francisca Carvajal, Karin Herrera, Paulina Núñez, Lilian Flores, Andrea Córdova, Gonzalo Pizarro, Pamela San Martín, Luis Contreras, Rodrigo Quera\",\"doi\":\"10.1016/j.gastrohep.2025.502437\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In ulcerative colitis (UC), STRIDE-II consensus has established the long-term goal of achieving endoscopic remission (ER), which helps reduce inflammatory burden, prevent permanent intestinal damage, and improve patient´s quality of life. However, achieving histological remission (HR) is also associated with a lower risk of experiencing outbreaks of inflammatory activity, the need for corticosteroids, hospitalizations, and the development of colorectal cancer.</p><p><strong>Objective: </strong>Evaluate the role of ER and HR in the development of inflammatory activity flares in patients who have achieved these long-term goals and are being followed in the Inflammatory Bowel Disease (IBD) Program.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on patients with UC treated in the IBD Program at the Universidad de los Andes, between January 2021 and April 2023. Patients with ER (Mayo Endoscopic Index [MEI] 0) or endoscopic response (MEI 1), with at least one year of follow-up, were included. HR was defined using the Nancy (<2), Geboes (<2), and Robarts (<3) indices. Inflammatory activity was assessed by a Partial Mayo Index (PMI) ≥2 and fecal calprotectin >250 µg/g.</p><p><strong>Results: </strong>A total of 84 patients were included, 57.1% were women, with a median age of 37 years (IQR 31-45). During follow-up, 71 patients continued in the study, and 24 (31%) experienced inflammatory flares. In the MEI 0 group, the percentage of flares at 12 and 44 months was 15% and 53%, respectively, compared to 43% and 67% in the MEI 1 group (p = 0.0302). PMI and fecal calprotectin levels were significantly lower in MEI 0 than in MEI 1 (p < 0.001 and p < 0.05, respectively). Although the Nancy, Geboes, and Robarts indices showed significant differences between MEI 0 and MEI 1, none were associated with a lower risk of flares in the MEI 0 group. No cases of colorectal neoplasia or need for surgery were reported during follow-up.</p><p><strong>Conclusion: </strong>In this cohort, ER is a significant predictor of the development of inflammatory flares in patients with UC, while HR did not show a clear impact in this regard. Further studies are needed to clarify the role of HR as a therapeutic target in UC.</p>\",\"PeriodicalId\":12802,\"journal\":{\"name\":\"Gastroenterologia y hepatologia\",\"volume\":\" \",\"pages\":\"502437\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterologia y hepatologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.gastrohep.2025.502437\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologia y hepatologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gastrohep.2025.502437","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:在溃疡性结肠炎(UC)中,STRIDE-II共识建立了实现内镜缓解(ER)的长期目标,这有助于减轻炎症负担,预防永久性肠道损伤,提高患者的生活质量。然而,实现组织学缓解(HR)也与经历炎症活动爆发、皮质类固醇需求、住院治疗和结直肠癌发展的较低风险相关。目的:评估ER和HR在炎症性肠病(IBD)项目中达到这些长期目标的患者炎症活动发作中的作用。材料和方法:在2021年1月至2023年4月期间,对洛斯安第斯大学IBD项目治疗的UC患者进行了回顾性研究。纳入随访至少1年的ER (Mayo内镜指数[MEI] 0)或内镜反应(MEI 1)患者。HR采用Nancy(250µg/g)测定。结果:共纳入84例患者,女性占57.1%,中位年龄37岁(IQR 31-45)。在随访期间,71例患者继续参与研究,24例(31%)出现炎症发作。在MEI 0组中,12个月和44个月的耀斑百分比分别为15%和53%,而MEI 1组为43%和67% (p = 0.0302)。MEI 0组PMI和粪钙保护蛋白水平显著低于MEI 1组(p < 0.001和p < 0.05)。虽然Nancy、Geboes和Robarts指数在MEI 0和MEI 1之间存在显著差异,但MEI 0组中没有任何与较低的耀斑风险相关。随访期间未发现结直肠肿瘤或需要手术的病例。结论:在本队列中,ER是UC患者炎症发作的重要预测因子,而HR在这方面没有明显的影响。需要进一步的研究来阐明HR作为UC治疗靶点的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluación de la Remisión en Colitis Ulcerosa: Relación entre Marcadores Clínicos, Endoscópicos e Histológicos como Predictores de Recaída.

Introduction: In ulcerative colitis (UC), STRIDE-II consensus has established the long-term goal of achieving endoscopic remission (ER), which helps reduce inflammatory burden, prevent permanent intestinal damage, and improve patient´s quality of life. However, achieving histological remission (HR) is also associated with a lower risk of experiencing outbreaks of inflammatory activity, the need for corticosteroids, hospitalizations, and the development of colorectal cancer.

Objective: Evaluate the role of ER and HR in the development of inflammatory activity flares in patients who have achieved these long-term goals and are being followed in the Inflammatory Bowel Disease (IBD) Program.

Materials and methods: A retrospective study was conducted on patients with UC treated in the IBD Program at the Universidad de los Andes, between January 2021 and April 2023. Patients with ER (Mayo Endoscopic Index [MEI] 0) or endoscopic response (MEI 1), with at least one year of follow-up, were included. HR was defined using the Nancy (<2), Geboes (<2), and Robarts (<3) indices. Inflammatory activity was assessed by a Partial Mayo Index (PMI) ≥2 and fecal calprotectin >250 µg/g.

Results: A total of 84 patients were included, 57.1% were women, with a median age of 37 years (IQR 31-45). During follow-up, 71 patients continued in the study, and 24 (31%) experienced inflammatory flares. In the MEI 0 group, the percentage of flares at 12 and 44 months was 15% and 53%, respectively, compared to 43% and 67% in the MEI 1 group (p = 0.0302). PMI and fecal calprotectin levels were significantly lower in MEI 0 than in MEI 1 (p < 0.001 and p < 0.05, respectively). Although the Nancy, Geboes, and Robarts indices showed significant differences between MEI 0 and MEI 1, none were associated with a lower risk of flares in the MEI 0 group. No cases of colorectal neoplasia or need for surgery were reported during follow-up.

Conclusion: In this cohort, ER is a significant predictor of the development of inflammatory flares in patients with UC, while HR did not show a clear impact in this regard. Further studies are needed to clarify the role of HR as a therapeutic target in UC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gastroenterologia y hepatologia
Gastroenterologia y hepatologia GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
1.50
自引率
10.50%
发文量
147
审稿时长
48 days
期刊介绍: Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信